ATAI Life Sciences aims to transform mental health care, backing companies working on new treatments for depression, anxiety and addiction. Now, it’s adding digital tools to the mix through a new company called IntroSpect Digital Therapeutics.
ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced…
JOIN THE ATAI #INSIGHTNETWORK